Insight
Bridging the gap: How can design research drive better healthcare outcomes for women?
By Hollie Johnston, Principal – Human Factors & Research at PDD, a global product and experience consultancy
It can no longer be argued that there is a data gap in women’s healthcare – with most available data historically biased towards men.
The underrepresentation of women in clinical research, often due to complexities of hormonal cycles has led to a lack of knowledge about drug impact on women.
Minimal research into support solutions for those suffering from endometriosis — which affects roughly 10 per cent (190 million) of reproductive-age women and girls globally — or the lack of consideration for physiological differences in load-bearing that lead to higher failure rates of certain hip implants in women than men, are just a few examples of how healthcare systems, shaped by incomplete data, have failed to address women’s specific needs, with consistent negative impacts on healthcare outcomes.
This data gap has huge implications for developing healthcare products, systems, and services.
It reinforces everyday experiences of bias and leads to unconscious bias when relying on Big Data. As AI technologies that emulate human intelligence and problem-solving capabilities advance, the risk of perpetuating inequality through incomplete and inaccurate datasets grows.
Designing better for women
As Caroline Criado Perez beautifully puts it in her book Invisible Women, “When designing, we need a woman in the room”.
From a design research perspective, this means considering the abilities, actions, and opinions of the intended user profile throughout the development process.
Even with the best of intentions, we cannot live another person’s experiences nor physically put ourselves in their shoes. If we tried, our conclusions would naturally be based on our experiences and understanding (inherent experience bias).
Including those with lived experience is a priority when planning research, not least when it comes to designing for women.
Consider a chronic condition such as endometriosis, which has a significant impact on the lives of sufferers.
Symptoms can vary from painful menstrual cramps and heavy menstrual bleeding, through to fatigue, and inability to get pregnant.
Symptoms can vary in type and severity over time – both during a monthly cycle, and over life stages.
Only by immersing ourselves in the lives and experiences of these women over an extended period can researchers and designers hope to understand the complexity of their needs, and therefore develop innovative and practical solutions that truly address them.

The woman in the room: Participant identification
As practitioners, delivering inclusive, user-driven solutions is at the heart of what we do.
A key component of development is identifying the correct stakeholders, identifying their needs and validating potential solutions with them.
This is where it becomes tricky.
On paper, proportional representation (where the proportion of participants recruited reflects the current real-world status) might seem like a valid method when recruiting.
In reality, in areas currently male-dominated, such as when researching ergonomics for cardiac surgeons, the needs and requirements of a much smaller female cohort would be significantly diluted, with potentially negative consequences in terms of device, system and service usability for women.
Therefore, participants should be selected on a case-by-case basis, using proportional representation as a starting point rather than a standard.
Building the stage: Study Setup
There are many ways to conduct design research and the method chosen should be relevant to the investigation topic. For example, evaluating a surgical tool might be best done in a surgical setting (or simulation lab).
Similarly, the setup of the evaluation should consider who is being evaluated.
Alzheimer’s, for example, is a disease that can be exacerbated by stress or change – such as the introduction of new people, activities, or equipment, all factors which are relevant to a research study.
When it comes to gender and sex, cultural and social factors might also be at play.
It may be inappropriate in some cultures, for example, for a woman to attend a solo face-to-face session or to speak to strangers about intimate health matters.
Study methodology is, therefore, critical to success.
When designing study methodology, it is important to consider not only technical objectives but also user profiles to ensure all demographics are adequately represented and evaluation methods do not negatively impact participation or study results.

Questioning your Insights: Translation & Analysis
Gathering the data is only one part of the puzzle; just as important is how we translate it and incorporate it into the development cycle to create actionable insights and form parameters for idea generation and selection.
At this stage it is all-too easy to fall back on assumptions and internal ‘knowledge’.
Instead, we should assess all ideas against the findings of our research to ensure they are grounded in actual user needs.
We must interrogate those ideas to understand what need they are meeting and why they are valuable.
We should also conduct an analysis to understand whether there are differences – or alignments – between cohorts and sub-cohorts.
Even within women’s health there may not be a ‘one size fits all’ solution. Take pregnancy tests, for example.
It can be safely assumed that taking a pregnancy test is an emotive time for most women; the result received, however, can be very polarising dependent on whether the user is actively trying to conceive, or not.
How do we ensure women are supported during this process – before, during and after test taking – when the response to the result can be so different?
The role of design research in shaping a more equitable healthcare future
The data gap in women’s healthcare is real. Not only is our physiology different, but so are our behaviours, attitudes, motivations, and cognition.
Passively relying on existing data or engaging the wrong stakeholders perpetuates the problem and misses opportunities for innovation.
In recent years, the rise of Femtech has opened the possibility to eventually close the data gap with wearable devices and companion apps to address the unmet health needs of women granting passive and active data collection for female-specific conditions (e.g. menopause, fertility, etc.).
But robust processes during product and service design, development, and evaluation remain crucial to ensure women’s distinct requirements are met.
Beyond product development, there is also scope to use design research and, more broadly, Human-Centred Design principles to drive change on a larger scale, influencing education, awareness, and policy.
A focus on organisational ergonomics, for example, applying HFE tools to organisational behaviour, can ensure that women’s needs are considered from the outset.
Crucially, addressing the data gap in women’s healthcare can set the scene to tackle further inequalities across genders, socio-economic groups and cultures.
Only by being aware of data limitations and actively collecting data to counteract them can we ensure we are designing for the right people in the right way and achieve healthcare equity for all.
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
News
WHO hosts parliamentary dialogue on women’s health
The World Health Organization (WHO) welcomed a delegation of parliamentarians to its Geneva headquarters for a high-level dialogue on women’s health and sexual and reproductive health and rights.
The meeting on 20 January 2026 focused on women’s health, sexual and reproductive health and rights, noncommunicable diseases (long-term conditions such as cancer and diabetes) and global health cooperation.
The exchange was convened by the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, bringing together parliamentarians from Albania, Germany, Georgia, Mexico, Slovakia, South Africa, Sri Lanka, Sweden and Zimbabwe.
A central theme was the need to move beyond fragmented approaches to women’s health.
Dr Alia El-Yassir, WHO director for gender, equity and diversity, highlighted that outcomes are shaped by gender inequalities, social norms and structural barriers across the life course, requiring coordinated action across health systems.
Thirty years after the Beijing Declaration and Platform for Action, a landmark framework adopted in 1995 to advance gender equality and women’s rights, Dr Anna Coates, WHO gender equality technical lead, noted that progress on women’s health remains uneven.
She called for health systems that are more gender-responsive and able to address women’s health holistically across the life course.
Parliamentarians stressed that health is inseparable from wider social and economic policies, and called for stronger links between evidence, legislation and measurable impact at country level.
The meeting also focused on sexual and reproductive health and rights, where parliamentarians expressed interest in engaging on issues that directly affect their constituents.
Dr Pascale Allotey, director of WHO’s Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and Ageing, outlined WHO’s life-course approach to sexual and reproductive health and rights.
She highlighted how needs evolve from birth to older age and how these are shaped by social determinants, humanitarian crises and demographic trends.
Dr Allotey underscored the role of parliamentarians in advancing sexual and reproductive health and rights and the importance of continued engagement with WHO to support evidence-based policy-making.
The agenda highlighted cancer as a growing priority for women’s health and for health system sustainability. Dr Prebo Barango, lead for the Cervical Cancer Elimination Initiative, Dr Meghan Doherty, consultant for palliative care, and Santiago Milan, lead for the WHO Global Platform for Access to Childhood Cancer Medicine, presented WHO’s integrated approach to cancer control.
Palliative care is treatment and support that aims to improve quality of life for people with serious illness by managing pain and other symptoms.
The discussion underlined the need for sustained political commitment and domestic investment to address noncommunicable diseases.
Parliamentarians shared national experiences showing the social and economic impacts of cancer on families and caregivers, reinforcing the importance of improving health literacy, reducing stigma and delivering people-centred care.
The meeting also addressed the state of global multilateralism.
Dr Jeremy Farrar, assistant director-general for health promotion, disease prevention and care, outlined how WHO has restructured to enhance efficiency, impact and capacity to support countries.
He reaffirmed WHO’s commitment to more systematic engagement with parliaments, recognising their role in shaping health policy, legislation and budgets.
The exchange concluded with a call for continued collaboration, including through partnerships with the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, ahead of the UNITE Global Summit 2026 on 6–7 March in Manila, the Philippines.
Insight
FDA approves Agilent test for ovarian cancer
Agilent has FDA approval for a test to identify ovarian cancer patients who may be eligible for immunotherapy.
Agilent’s PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic to help identify patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours express PD-L1 and who may be eligible for treatment with KEYTRUDA, Merck’s anti-PD-1 therapy.
A companion diagnostic is a test used alongside a specific treatment to show whether a patient is suitable for that therapy. PD-L1 is a protein on some cancer cells that helps tumours evade the immune system.
These cancers affect the reproductive system and the lining of the abdominal cavity.
The test enables pathologists to assess PD-L1 expression at diagnosis to support treatment decisions in a disease where options remain limited for many.
This is the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA.
Nina Green, vice president and general manager of Agilent’s clinical diagnostics division, said: “Delivering effective precision oncology requires close collaboration between diagnostics and therapeutics, and this FDA approval reflects Agilent’s long-standing industry partnership in companion diagnostics.
“We are proud to enable pathologists to identify patients with EOC who may benefit from immunotherapy.
“As the first immuno-oncology approval for this disease, this milestone underscores our commitment to advancing precision medicine and expanding access to innovative cancer treatments worldwide.”
PD-L1 expression with this test was evaluated in the KEYNOTE-B96 clinical trial supporting its use to identify patients who may benefit from KEYTRUDA.
In the US, ovarian cancer caused approximately 12,730 deaths in 2025 and the five-year survival rate was 51.6 per cent between 2015 and 2021.
In addition to these cancer types, the test is indicated in the US to help identify patients with non-small cell lung cancer, oesophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer and gastric or gastro-oesophageal junction adenocarcinoma who may benefit from treatment with KEYTRUDA.
The test was developed by Agilent with Merck as a companion diagnostic for KEYTRUDA.
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health




